Marc H. Hedrick, M.D. President
Dr. Marc H. Hedrick was appointed President in May 2004. Dr. Hedrick joined Cytori Therapeutics as Chief Scientific Officer, Medical Director and Director in October 2002. Previously, Dr. Hedrick co-founded, and served as President and Chief Executive Officer of StemSource, Inc., a company specializing in stem cell research and development. Dr. Hedrick, a plastic surgeon by training, is a former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). From 1998 until 2005, Dr. Hedrick directed the Laboratory of Regenerative Bioengineering and Repair for the Department of Surgery at UCLA. Dr. Hedrick obtained his M.D. from the University of Texas Southwestern Medical School, Dallas.
Mark E. Saad- Chief Financial Officer
Mark E. Saad joined Cytori Therapeutics as Chief Financial Officer in June 2004. Previously, Mr. Saad served as Chief Operating Officer of UBS, Healthcare Investment Banking, New York, where he was responsible for global investment banking operations. Upon joining UBS, Mr. Saad served as Executive Director covering life sciences sectors - biotechnology and medical devices. Prior to joining UBS, Mr. Saad held the position of Financial Analyst/Associate with Salomon, Smith Barney, Healthcare Investment Banking, New York, where he managed public and private transactions. Mr. Saad holds a B.A. from Villanova University, Philadelphia, PA.
Their performance from a shareholder´s perspective
If you have read the article on the frontpage "The fine art of Calhouning" you will have understood that a lot has been left to be desired from a shareholders perspective in respect of performance and management execution by this team during the past 10 years or so. The sharecount increased by a whopping 300% in the last five years- from 14 Mio shares OS to > 55 Mio as we speak (all non-diluted that is- before adding warrants and options outstanding) and those shares were always added at very low share prices, when the bottom of the Companies wallet could be seen. Some folks even believe that changes to the team are required to be made, if the execution in respect of prior promises dont get materialized any time soon.
One of those promises, which have been outstanding since late 2006, is the conclusion of one or more non-dilutive therapeutic partner deals to end the dilution once and for all and accelerate the development of that wonderful regenerative goldmine, which the technology really represents.
This of course assumes, that the infamous "inflection point", which this team already could "smell" in late 2009 can be reached before this non-dilutive money is spent.
Personally I am as always optimistic, that the article "The fine art of Calhouning" can be archived some time soon and will be replaced by content singing the praise of considerable achievements.
The pressure is definitely on- time to deliver and start the journey to at least "10 times our wildest dreams", which the technology of Cytori is all about.
Embedded in the above text you will find a video which Reuters made at the end of 2010, which was recorded at Callan Road in San Diego.
Below you will find two other "recordings from the past"- Calhouns presentation at the BioMed in 2010 and an interview that Mark Saad did at Bloomberg somewhere in 2009. All videos are hosted locally on my server and cannot be found anywhere else (to my knowledge)